Lapatinib utilization review in the treatment of breast cancer at a general hospital

• Eva María Martín Gozalo ^[1] ; Marta Hernández Segurado ^[1] ; María Ángeles Arias Moya ; Macarena Bonilla Porras ; Francisco Javier Bécares Martínez ; Eva Castillo Bazán
  1. [1] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 17, Nº. 3, 2015, pág. 9
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Describe the results obtained with the use of lapatinib in the treatment of metastatic breast cancer in combination with capecitabine or trastuzumab.

    Method: Observational, retrospective study. Patients who started treatment with lapatinib between May 2010 and May 2014. Data were collected from medical histories.

    Results: 29 patients with metastatic breast cancer (mean age 60.9 years) were included.

    In 10 patients (34.5􀀈%), lapatinib was used in first line, 15 patients (51.7􀀈%) in the second line, two patients (6.9%) in the third line and two patients (6.9%) in fourth line. Nine patients had brain metastases. Median progression-free survival was 4.93 months and median overall survival 15 months.

    Conclusion: Lapatinib in combination with capecitabine in routine practice does not seem to be similar as the published trials. And patients treated with lapatinib in metastatic first line therapy had worse outcomes than those treated in second or third line like data sheet recommended to do